



**FOR IMMEDIATE RELEASE**

**CONTACT:**

Gwynne Oosterbaan  
+1 (646) 258-8410 (mobile)  
[gwynne.oosterbaan@tballiance.org](mailto:gwynne.oosterbaan@tballiance.org)

Bea Evangelista  
+ 1 (212) 227-7540 ext 202  
[beatrice.evangelista@tballiance.org](mailto:beatrice.evangelista@tballiance.org)

**Ann Ginsberg, M.D., Ph.D. Named Head of Clinical Development  
at the Global Alliance for TB Drug Development**

**NEW YORK, NY - JUNE 9, 2004** – The Global Alliance for TB Drug Development (TB Alliance), a public-private partnership accelerating the discovery and development of more effective and affordable tuberculosis (TB) medicines, announced the appointment of Dr. Ann Ginsberg as Head of Clinical Development. A highly-regarded TB expert, Dr. Ginsberg was Director for Project Management at Merck & Co., Inc. for the past two years. Dr. Ginsberg also brings 15 years of experience with the National Institutes of Health (NIH), where she last served as Chief of Respiratory Diseases of the National Institute of Allergy and Infectious Diseases (NIAID).

"Dr. Ginsberg is an outstanding addition to the TB Alliance R&D team led by Dr. Spigelman," said Dr. Maria C. Freire, Chief Executive Officer of the TB Alliance. "She joins us at the perfect time, as we gear up for the clinical phase in the development of our lead compounds."

Working closely with Dr. Mel Spigelman, Director of Research and Development, Dr. Ginsberg will oversee the clinical development plans of promising compounds and design the clinical strategies necessary for their effective and rapid regulatory approval.

"The Alliance has made great strides in a few short years and Dr. Ginsberg's appointment underlines how rapidly it has built and advanced the portfolio," said Dr. Lee Reichman, Executive Director at the New Jersey Medical School National Tuberculosis Center and President of the TB Alliance's Stakeholders' Association. "This represents quite a coup for the TB Alliance. Her TB expertise and knowledge of industry decision-making will undoubtedly contribute to the Alliance's further momentum."

"I am eager for the challenges this new position holds," said Dr. Ann Ginsberg, Head of Clinical Development. "I look forward to working with friends from the TB community and bringing to bear my prior experience in both the public and private sectors to ensure that novel therapies reach TB patients everywhere."

Trained as a molecular biologist and pathologist, Dr. Ginsberg holds a B.A. from Harvard University, an M.D. from Columbia University and a Ph.D. from Washington University. Board Certified in Anatomic Pathology, she is the author of numerous scientific publications and recipient of several prominent awards, including the Department of Health and Human Services Secretary's Award for Distinguished Service in 2000. She has served on multiple global health committees, and is currently a member of the Board of Directors of the Aeras TB Vaccine Foundation.

**About the Global Alliance for TB Drug Development**

The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit, public-private partnership accelerating the discovery and/or development of affordable, new anti-TB drugs that will shorten treatment, be effective against multi-drug resistant strains, and improve treatment of latent infection. The TB Alliance builds a portfolio of promising drug candidates, manages their development through cooperative deals with public and private partners, and provides staged funding and expert scientific and management guidance. Current R&D partners include the Korean Research Institute of Chemical Technology (KRICT), Wellesley College, Johns Hopkins University, the International Union Against Tuberculosis and Lung Disease (IUATLD), and the Research Triangle Institute. For more information, visit <http://www.tballiance.org>.

###